JP2007514749A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007514749A5 JP2007514749A5 JP2006545434A JP2006545434A JP2007514749A5 JP 2007514749 A5 JP2007514749 A5 JP 2007514749A5 JP 2006545434 A JP2006545434 A JP 2006545434A JP 2006545434 A JP2006545434 A JP 2006545434A JP 2007514749 A5 JP2007514749 A5 JP 2007514749A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- toxoid
- clostridium difficile
- antibiotic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 241000193163 Clostridioides difficile Species 0.000 claims 6
- 230000003115 biocidal effect Effects 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 3
- 231100000765 toxin Toxicity 0.000 claims 3
- 239000003053 toxin Substances 0.000 claims 3
- 241000193403 Clostridium Species 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 231100001102 clostridial toxin Toxicity 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- MYPYJXKWCTUITO-KIIOPKALSA-N chembl3301825 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)C(O)[C@H](C)O1 MYPYJXKWCTUITO-KIIOPKALSA-N 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims 1
- 229960000282 metronidazole Drugs 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/737,270 | 2003-12-16 | ||
| US10/737,270 US6969520B2 (en) | 1997-10-20 | 2003-12-16 | Active immunization against clostridium difficile disease |
| PCT/US2004/042277 WO2005058353A1 (en) | 2003-12-16 | 2004-12-15 | Passive immunization against clostridium difficile disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011195944A Division JP6130622B2 (ja) | 2003-12-16 | 2011-09-08 | クロストリジウムディフィシル疾患に対する受動免疫感作 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007514749A JP2007514749A (ja) | 2007-06-07 |
| JP2007514749A5 true JP2007514749A5 (enExample) | 2008-07-03 |
| JP4904163B2 JP4904163B2 (ja) | 2012-03-28 |
Family
ID=34700454
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006545434A Expired - Fee Related JP4904163B2 (ja) | 2003-12-16 | 2004-12-15 | クロストリジウムディフィシル疾患に対する受動免疫感作 |
| JP2011195944A Expired - Lifetime JP6130622B2 (ja) | 2003-12-16 | 2011-09-08 | クロストリジウムディフィシル疾患に対する受動免疫感作 |
| JP2015149504A Ceased JP2015205919A (ja) | 2003-12-16 | 2015-07-29 | クロストリジウムディフィシル疾患に対する受動免疫感作 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011195944A Expired - Lifetime JP6130622B2 (ja) | 2003-12-16 | 2011-09-08 | クロストリジウムディフィシル疾患に対する受動免疫感作 |
| JP2015149504A Ceased JP2015205919A (ja) | 2003-12-16 | 2015-07-29 | クロストリジウムディフィシル疾患に対する受動免疫感作 |
Country Status (7)
| Country | Link |
|---|---|
| US (6) | US6969520B2 (enExample) |
| EP (2) | EP1708743B1 (enExample) |
| JP (3) | JP4904163B2 (enExample) |
| AU (2) | AU2004299105B8 (enExample) |
| CA (1) | CA2550108C (enExample) |
| DK (1) | DK1708743T3 (enExample) |
| WO (1) | WO2005058353A1 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6969520B2 (en) * | 1997-10-20 | 2005-11-29 | Acambis Inc. | Active immunization against clostridium difficile disease |
| GB0306782D0 (en) * | 2003-03-25 | 2003-04-30 | Neutec Pharma Plc | Treatment of infection due to clostridium difficile |
| US20070280949A1 (en) * | 2003-07-10 | 2007-12-06 | Michelle Alfa | Combination Therapy for Gastroenteric Diseases Caused by Microorganisms |
| EP1682572A4 (en) * | 2003-10-24 | 2009-01-28 | Univ Queensland | Protein Expression |
| WO2005106598A1 (ja) * | 2004-04-28 | 2005-11-10 | Canon Kabushiki Kaisha | トナー |
| US20090087478A1 (en) * | 2004-12-27 | 2009-04-02 | Progenics Pharmaceuticals (Nevada), Inc. | Orally Deliverable and Anti-Toxin Antibodies and Methods for Making and Using Them |
| JPWO2007072916A1 (ja) * | 2005-12-22 | 2009-06-04 | 財団法人化学及血清療法研究所 | 卵内接種用ワクチン |
| ES2507553T3 (es) * | 2006-08-02 | 2014-10-15 | Johannes Gutenberg-Universität Mainz | Fármaco contra intoxicaciones por LCT |
| CN101855336B (zh) * | 2007-09-14 | 2019-07-30 | 赛诺菲巴斯德生物制剂有限责任公司 | 含艰难梭菌类毒素a和b的药物组合物 |
| EP2244735A4 (en) | 2007-10-02 | 2011-02-23 | Avaxia Biologics Inc | ANTIBODY THERAPY FOR USE IN THE DIGESTIVE TUBE |
| WO2010036826A1 (en) * | 2008-09-24 | 2010-04-01 | Sanofi Pasteur Biologics Co. | Methods and compositions for increasing toxin production |
| CA2752815A1 (en) | 2009-02-20 | 2010-08-26 | Health Protection Agency | Antibodies to clostridium difficile toxins |
| JP5408017B2 (ja) * | 2009-06-05 | 2014-02-05 | 株式会社デンソー | 蓄冷熱交換器 |
| GB0921288D0 (en) | 2009-12-04 | 2010-01-20 | Health Prot Agency | Therapies for preventing or suppressing clostridium difficile infection |
| DK4032586T3 (da) | 2010-02-01 | 2025-11-10 | Ferring Microbiome Inc | Bakterieterapi til clostridium difficile-colitis |
| US8431361B2 (en) * | 2010-09-17 | 2013-04-30 | Board Of Regents Of The University Of Oklahoma | Bacterial cells, optimized nucleotide sequences and methods for improved expression of recombinant Clostridium difficile toxin B |
| CA2824964C (en) | 2011-01-19 | 2019-01-08 | Accessclosure, Inc. | Apparatus and methods for sealing a vascular puncture |
| GB201105981D0 (en) * | 2011-04-08 | 2011-05-18 | Glaxosmithkline Biolog Sa | Novel process |
| TWI815599B (zh) | 2011-04-22 | 2023-09-11 | 美商惠氏有限責任公司 | 與難養芽胞梭菌（Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ）之突變毒素有關之組成物及彼之方法 |
| US10364298B2 (en) | 2011-11-18 | 2019-07-30 | National Research Council Of Canada | Clostridium difficile lipoteichoic acid and uses thereof |
| AR089797A1 (es) | 2012-01-27 | 2014-09-17 | Merck Sharp & Dohme | Vacunas contra clostridum difficile que comprenden toxinas recombinantes |
| CN104203976A (zh) | 2012-03-02 | 2014-12-10 | 瑞泽恩制药公司 | 艰难梭状芽孢杆菌毒素的人源抗体 |
| JPWO2014061783A1 (ja) | 2012-10-19 | 2016-09-05 | 株式会社イーベック | クロストリジウム・ディフィシルの毒素に特異的なヒト抗体もしくはその抗原結合性断片 |
| BR122016023101B1 (pt) | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile |
| WO2014135891A1 (en) | 2013-03-08 | 2014-09-12 | Cipla Limited | Pharmaceutical compositions for rectal administration |
| EP2969012A4 (en) | 2013-03-12 | 2016-09-14 | Univ Yale | COMPOSITIONS AND METHODS FOR IDENTIFYING SEQUENCEL ANTIBODY-BONDED MICROBES |
| WO2014144567A2 (en) * | 2013-03-15 | 2014-09-18 | Sanofi Pasteur, Inc. | Toxoid, compositions and related methods |
| AU2014228983B2 (en) | 2013-03-15 | 2018-04-05 | Sanofi Pasteur, Inc. | Toxoid, compositions and related methods |
| EP2986316B1 (en) * | 2013-04-19 | 2023-01-25 | Immuron Limited | Methods and compositions for the treatment and/or prophylaxis of clostridium difficile associated disease |
| US9782445B2 (en) | 2013-06-05 | 2017-10-10 | Rebiotix, Inc. | Microbiota restoration therapy (MRT), compositions and methods of manufacture |
| PT3003330T (pt) | 2013-06-05 | 2018-10-10 | Rebiotix Inc | Terapêutica da restauração da microbiota (trm), composições e processos de fabrico |
| US9511100B2 (en) | 2013-06-05 | 2016-12-06 | Rebiotix, Inc. | Microbiota restoration therapy (MRT), compositions and methods of manufacture |
| US9694039B2 (en) | 2013-06-05 | 2017-07-04 | Rebiotix, Inc. | Microbiota restoration therapy (MRT), compositions and methods of manufacture |
| US10383901B2 (en) | 2013-06-05 | 2019-08-20 | Rebiotix, Inc. | Microbiota restoration therapy (MRT), compositions and methods of manufacture |
| US9511099B2 (en) | 2013-06-05 | 2016-12-06 | Rebiotix, Inc. | Microbiota restoration therapy (MRT), compositions and methods of manufacture |
| CN105611942A (zh) | 2013-06-14 | 2016-05-25 | 圣诺菲·帕斯图尔公司 | 针对艰难梭菌免疫的组合物和方法 |
| EP2957570B1 (en) * | 2014-06-20 | 2019-04-17 | Immunimed Inc. | Polyclonal antibodies against clostridium difficile and uses thereof |
| US10513552B2 (en) | 2014-06-20 | 2019-12-24 | Immunimed Inc. | Use of polyclonal antibodies against clostridium difficile for treatment of inflammatory bowel disease |
| WO2016033439A2 (en) * | 2014-08-28 | 2016-03-03 | Yale University | Compositions and methods for the treating an inflammatory disease or disorder |
| CN107708729A (zh) * | 2015-04-15 | 2018-02-16 | 免疫医疗公司 | 用于治疗艰难梭菌（clostridium difficile）感染和相关疾病的方法 |
| US10828340B2 (en) | 2015-06-09 | 2020-11-10 | Rebiotix, Inc. | Microbiota restoration therapy (MRT) compositions and methods of manufacture |
| BR112017026586B1 (pt) | 2015-06-09 | 2021-11-03 | Rebiotix, Inc. | Composições de terapia de restauração de microbiota (mrt) e métodos de fabricação |
| US10799539B2 (en) | 2015-06-09 | 2020-10-13 | Rebiotix, Inc. | Microbiota restoration therapy (MRT) compositions and methods of manufacture |
| US10905726B2 (en) | 2015-06-09 | 2021-02-02 | Rebiotix, Inc. | Microbiota restoration therapy (MRT) compositions and methods of manufacture |
| EP3344276B1 (en) | 2015-09-03 | 2020-04-22 | The Board of Regents of the University of Oklahoma | Peptide inhibitors of clostridium difficile tcdb toxin |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US968199A (en) * | 1909-11-24 | 1910-08-23 | Nathan Schwartz | Muffler. |
| US4581020A (en) * | 1983-07-18 | 1986-04-08 | Trimedyne, Inc. | Medication delivery device and system for percutaneous administration of medication |
| US4713240A (en) * | 1985-04-04 | 1987-12-15 | Research Corporation | Vaccines based on insoluble supports |
| US5244657A (en) | 1987-11-24 | 1993-09-14 | Connaught Laboratories Limited | Genetic detoxification of pertussis toxin |
| GB8727489D0 (en) | 1987-11-24 | 1987-12-23 | Connaught Lab | Detoxification of pertussis toxin |
| US5221618A (en) | 1987-11-24 | 1993-06-22 | Connaught Laboratories Limited | Genetic detoxification of pertussis toxin |
| US5358868A (en) | 1987-11-24 | 1994-10-25 | Connaught Laboratories Limited | Genetic detoxification of pertussis toxin |
| US5332583A (en) | 1987-11-24 | 1994-07-26 | Connaught Laboratories Limited | Vaccine containing genetically-detoxified pertussis holotoxin |
| US5919665A (en) * | 1989-10-31 | 1999-07-06 | Ophidian Pharmaceuticals, Inc. | Vaccine for clostridium botulinum neurotoxin |
| US5599539A (en) | 1989-10-31 | 1997-02-04 | Ophidian Pharmaceuticals, Inc. | Therapy for clostridial botulinum toxin |
| US5601823A (en) | 1989-10-31 | 1997-02-11 | Ophidian Pharmaceuticals, Inc. | Avian antitoxins to clostridium difficle toxin A |
| AU668092B2 (en) | 1991-04-22 | 1996-04-26 | Massachusetts Health Research Institute, Inc. | Process of screening plasma samples for effective antibody titers against respiratory viruses |
| US6221363B1 (en) * | 1991-07-11 | 2001-04-24 | Baxter Aktiengesellschaft | Vaccine for the prevention of lyme disease |
| WO1994015640A1 (en) | 1993-01-12 | 1994-07-21 | Anthony George Gristina | Methods and compositions for the direct concentrated delivery of passive immunity |
| US5562909A (en) | 1993-07-12 | 1996-10-08 | Massachusetts Institute Of Technology | Phosphazene polyelectrolytes as immunoadjuvants |
| US5538733A (en) * | 1994-07-07 | 1996-07-23 | Willmar Poultry Company, Inc. | Method of priming an immune response in a one-day old animal |
| JPH10505358A (ja) * | 1994-09-06 | 1998-05-26 | ギャラゲン・インコーポレイテッド | クロストリジウム・ディフィシル関連疾患の治療処置 |
| EP0796326A4 (en) | 1994-10-24 | 2000-01-19 | Ophidian Pharm Inc | VACCINE AND ANTITOXIN FOR THE TREATMENT AND PREVENTION OF C. DIFFICILE DISEASE |
| US6967088B1 (en) * | 1995-03-16 | 2005-11-22 | Allergan, Inc. | Soluble recombinant botulinum toxin proteins |
| US5919463A (en) * | 1995-07-07 | 1999-07-06 | Oravax, Inc. | Clostridium difficle toxins as mucosal adjuvants |
| WO1997002836A1 (en) | 1995-07-07 | 1997-01-30 | Oravax, Inc. | Clostridium difficile toxins as mucosal adjuvants |
| EP0877623A1 (en) | 1995-07-07 | 1998-11-18 | Oravax, Inc. | Intranasal vaccination against gastrointestinal disease |
| ES2248822T3 (es) | 1995-09-15 | 2006-03-16 | Dale N. Gerding | Procedimientos y composiciones para la prevencion y el tratamiento de enfermedades asociadas al clostridium difficile. |
| ES2224273T3 (es) * | 1996-09-30 | 2005-03-01 | University Of Arkansas | Metodo para producir inmunidad activa por medio de un conjugado de vacuna. |
| US20050106157A1 (en) * | 1997-05-27 | 2005-05-19 | Deckers Harm M. | Immunogenic formulations comprising oil bodies |
| AU754270B2 (en) | 1997-10-20 | 2002-11-07 | Sanofi Pasteur Biologics, Llc | Passive immunization against clostridium difficile disease |
| US6969520B2 (en) * | 1997-10-20 | 2005-11-29 | Acambis Inc. | Active immunization against clostridium difficile disease |
| TW200500071A (en) * | 2002-08-29 | 2005-01-01 | Activbiotics Inc | Methods and reagents for treating infections of clostridium difficile and diseases associated therewith |
-
2003
- 2003-12-16 US US10/737,270 patent/US6969520B2/en not_active Expired - Lifetime
-
2004
- 2004-12-15 AU AU2004299105A patent/AU2004299105B8/en not_active Ceased
- 2004-12-15 WO PCT/US2004/042277 patent/WO2005058353A1/en not_active Ceased
- 2004-12-15 JP JP2006545434A patent/JP4904163B2/ja not_active Expired - Fee Related
- 2004-12-15 DK DK04814456.2T patent/DK1708743T3/en active
- 2004-12-15 EP EP04814456.2A patent/EP1708743B1/en not_active Revoked
- 2004-12-15 CA CA2550108A patent/CA2550108C/en not_active Expired - Fee Related
- 2004-12-15 EP EP11002684A patent/EP2394658A3/en not_active Withdrawn
-
2005
- 2005-09-26 US US11/235,609 patent/US20060029608A1/en not_active Abandoned
-
2007
- 2007-05-30 US US11/755,459 patent/US20070231336A1/en not_active Abandoned
-
2011
- 2011-04-20 AU AU2011201804A patent/AU2011201804B2/en not_active Ceased
- 2011-09-08 JP JP2011195944A patent/JP6130622B2/ja not_active Expired - Lifetime
-
2012
- 2012-04-27 US US13/457,821 patent/US9226956B2/en not_active Expired - Fee Related
-
2014
- 2014-10-10 US US14/512,216 patent/US20150030612A1/en not_active Abandoned
-
2015
- 2015-07-29 JP JP2015149504A patent/JP2015205919A/ja not_active Ceased
-
2016
- 2016-01-04 US US14/986,895 patent/US20160287689A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007514749A5 (enExample) | ||
| RU2010140682A (ru) | Способ лечения пациента от инфекции, фармацевтическая композиция (варианты) и лекарственное средство | |
| JP2006501240A5 (enExample) | ||
| CN115698079A (zh) | 抗cd79b抗体药物偶联物、其制备方法及其医药用途 | |
| BRPI0513200A (pt) | uso de um anticorpo anti-igf-1r na preparação de um medicamento para tratamento combinado para malignidades não-hematológicas | |
| JP2015519329A5 (enExample) | ||
| HRP20170056T2 (hr) | Terapija male učestalosti glatiramer acetatom | |
| JP2009500443A5 (enExample) | ||
| IL171607A (en) | Use of botulinum toxin for the treatment of sinusitis-induced headaches | |
| PE20142319A1 (es) | Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero | |
| JP2013503165A5 (enExample) | ||
| JP2009515901A5 (enExample) | ||
| EA201592040A1 (ru) | Иммуногенная композиция для применения в терапии | |
| OA12845A (en) | Single dose azithromycin for treating respiratory infections. | |
| JP2006514681A5 (enExample) | ||
| JP2002530353A5 (enExample) | ||
| WO2001062799A3 (en) | Method for inhibiting angiogenesis using molecules that enhance plasmin activity | |
| JP2009500045A5 (enExample) | ||
| Ramam et al. | A two-step schedule for the treatment of actinomycotic mycetomas. | |
| JP2005507888A5 (enExample) | ||
| CA2519789A1 (en) | Aplidine for multiple myeloma treatment | |
| Buckland et al. | Upper limb morbidity as a direct consequence of intravenous drug abuse | |
| JP2011500650A5 (enExample) | ||
| Wilson | Streptomycin in Non-tuberculous Infections | |
| JP2001316293A5 (enExample) |